Dataset Information


Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.

ABSTRACT: Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR). In theory, more potent radiosensitizing drugs should increase tumour kill and improve patient outcomes. In practice, clinical utility of potent radiosensitizing drugs is curtailed by off-target side effects. Here we report potent anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize to tumours based on surface receptor expression. While two classes of potent anti-tubulins, auristatins and maytansinoids, indiscriminately radiosensitize tumour cells, conjugating these potent anti-tubulins to anti-ErbB antibodies restrict their radiosensitizing capacity. Of translational significance, we report that a clinically used maytansinoid ADC, ado-trastuzumab emtansine (T-DM1), with IR prolongs tumour control in target expressing HER2+ tumours but not target negative tumours. In contrast to ErbB signal inhibition, our findings establish an alternative therapeutic paradigm for ErbB-based radiosensitization using antibodies to restrict radiosensitizer delivery.


PROVIDER: S-EPMC5059467 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5893532 | BioStudies
1000-01-01 | S-EPMC5364507 | BioStudies
2014-01-01 | S-EPMC4502390 | BioStudies
2019-01-01 | S-EPMC6805470 | BioStudies
2015-01-01 | S-EPMC4458508 | BioStudies
1000-01-01 | S-EPMC2967058 | BioStudies
2020-01-01 | S-EPMC6946877 | BioStudies
2014-01-01 | S-EPMC4649524 | BioStudies
2017-01-01 | S-EPMC5530949 | BioStudies
2020-01-01 | S-EPMC7060130 | BioStudies